Mipasetamab Biosimilar – A Novel Anti-AXL mAb for Targeted Therapy
Mipasetamab Biosimilar is a research-grade monoclonal antibody (mAb) that specifically targets the AXL receptor tyrosine kinase (AXL), a therapeutic target implicated in various cancers and inflammatory diseases. This innovative antibody is designed to mimic the structure and function of the original mipasetamab, a fully humanized anti-AXL mAb currently in clinical development.
Structure of Mipasetamab Biosimilar
Mipasetamab Biosimilar is a recombinant, chimeric IgG1 mAb produced in Chinese hamster ovary (CHO) cells. It consists of two identical heavy chains and two identical light chains, each containing a variable region that recognizes the AXL protein and a constant region that mediates effector functions.
The variable region of Mipasetamab Biosimilar is derived from the original mipasetamab, which binds to a specific epitope on the extracellular domain of AXL with high affinity and specificity. The constant region is engineered to have reduced Fc-mediated effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), to minimize potential side effects.
Mechanism of Action
AXL is a receptor tyrosine kinase that plays a critical role in cell survival, proliferation, and migration. Aberrant activation of AXL has been implicated in tumor growth, metastasis, and resistance to chemotherapy and targeted therapies. Mipasetamab Biosimilar works by binding to AXL and blocking its downstream signaling pathways, thereby inhibiting tumor growth and metastasis.
Moreover, Mipasetamab Biosimilar can also induce internalization and degradation of AXL, leading to decreased expression of AXL on the cell surface. This mechanism of action is distinct from other anti-AXL therapies, which primarily target the extracellular domain of AXL and do not induce internalization.
Therapeutic Applications Mipasetamab Biosimilar has shown promising preclinical results in various
cancer models, including breast, lung, ovarian, and pancreatic cancers. It has also demonstrated efficacy in combination with other anti- cancer agents, such as chemotherapy and immune checkpoint inhibitors.
In addition to its potential in cancer therapy, Mipasetamab Biosimilar has also been investigated in inflammatory diseases, such as rheumatoid arthritis and systemic lupus erythematosus. AXL has been implicated in the pathogenesis of these diseases, and targeting AXL with Mipasetamab Biosimilar has shown promising results in preclinical studies.
Advantages of Mipasetamab Biosimilar
Mipasetamab Biosimilar offers several advantages over other anti-AXL therapies. Its fully humanized structure reduces the risk of immunogenicity and potential side effects associated with non-human antibodies. Its unique mechanism of action, inducing internalization and degradation of AXL, may provide additional benefits in terms of efficacy and safety.
Furthermore, Mipasetamab Biosimilar is being developed as a biosimilar, which means it has a highly similar structure and function to the original mipasetamab. This allows for a faster and more cost-effective development process, potentially making this therapy more accessible to patients in need.
Conclusion
Mipasetamab Biosimilar is a novel anti-AXL mAb with a unique structure, mechanism of action, and potential therapeutic applications in cancer and inflammatory diseases. Its promising preclinical results and advantages over other anti-AXL therapies make it a promising candidate for targeted therapy. Further clinical studies are needed to fully evaluate the efficacy and safety of this antibody, but it holds great potential for improving patient outcomes in various diseases.
There are no reviews yet.